BARDA has picked Start2 to run a US$100m prize for broad-spectrum antivirals, launching in early 2026.
The multi-stage competition will seek small-molecule drugs that work against multiple viruses (“broad-spectrum”). Small-molecule therapies are typically oral chemical compounds.
Start2 will design, promote and administer the contest via BARDA’s VITAL Hub. The aim is to back candidates that can move towards clinical trials and, ultimately, US regulatory approval. Approaches may include AI-enabled drug discovery and design.
Annika Pierson, CEO of Start2 Group, Inc., said: “We are honoured to partner with BARDA to lead this prize competition that draws in new innovators, lowers barriers of entry for new researchers and approaches, and rewards scientific translational breakthroughs with the potential to advance into the clinic and achieve FDA approval. I’m excited that Start2 is partnering with BARDA on another important innovation competition, building on our collaborative relationship.”
BARDA, part of the US Department of Health and Human Services’ Administration for Strategic Preparedness and Response, has committed at least US$100m. The project is funded under Other Transaction number 75A50124C00012.
